Pyruvate has a remarkable protective effect against zinc neurotoxicity. Because zinc neurotoxicity is likely one of the key mechanisms of ischemic brain injury, the neuroprotective effect of pyruvate was tested in a rat model of transient forebrain ischemia. Control experiments in mouse cortical culture showed that pyruvate almost completely blocked zinc toxicity but did not attenuate calcium-overload neuronal death. Adult rats subjected to 12 min forebrain ischemia exhibited widespread zinc accumulation and neuronal death throughout hippocampus and cortex 72 hr after reperfusion. However, rats injected intraperitoneally with sodium pyruvate (500-1000 mg/ kg) within 1 hr after 12 min forebrain ischemia showed almost no neuronal death. In addition, the mortality was markedly decreased in the pyruvate-protected groups (3.8%) compared with the NaCl-injected control group (58.1%). The neuroprotective effect persisted even at 30 d after the insult. The spectacular protection without noticeable side effects makes pyruvate a promising neuroprotectant in human ischemic stroke.
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Key words: zinc neurotoxicity; glycolysis; excitotoxicity; glutamate antagonist; stroke; ATP; NAD ϩ Neurons in the forebrain are highly vulnerable to ischemia (Pulsinelli et al., 1982; Smith et al., 1984) . Only a few minutes of ischemia can cause death of vulnerable neurons in hippocampus and neocortex. Neuronal death in ischemic conditions may be brought about by a chain of events (failed energy metabolism, membrane depolarization, glutamate release, and toxic calcium influx) that comprise the vicious circle of calcium excitotoxicity (Choi and Rothman, 1990; Choi, 1995) .
In addition to calcium, endogenous zinc may play a role as an ionic mediator of neuronal cell death (Choi and Koh, 1998; Weiss et al., 2000) . Forebrain contains a substantial pool of chelatable zinc inside vesicles of certain excitatory synaptic boutons (Frederickson, 1989; Palmiter et al., 1996; Wenzel et al., 1997) that is released with neuronal activity or membrane depolarization (Assaf and Chung, 1984; Howell et al., 1984; Aniksztejn et al., 1987; Vogt et al., 2000) . After brain ischemia, concurrent with depletion of presynaptic bouton zinc, accumulation of zinc in the cell body of vulnerable neurons occurs (Tonder et al., 1990; Koh et al., 1996) . Furthermore, blockade of the zinc movement with the metal chelator CaEDTA, markedly reduces ischemic neuronal death (Koh et al., 1996; Park et al., 2000) . These results suggest that the interneuronal movement of zinc is a key mechanism of ischemic neuronal death.
Zinc can enter neurons via various Ca 2ϩ routes, such as NMDA channels, Ca 2ϩ -permeable AMPA/kainate channels, voltage-gated Ca 2ϩ channels, and Na ϩ /Ca 2ϩ exchangers (Choi and Koh, 1998; Weiss et al., 2000) , which are activated by coreleased glutamate. To highlight the fact that endogenous zinc, in addition to or instead of Ca 2ϩ , can mediate glutamate neurotoxicity in certain cases, Frederickson et al (2000) coined the term "zinc excitotoxicity" as opposed to conventional "calcium excitotoxicity." Inside neurons, zinc may activate various cell death cascades, such as free radical generation and caspase activation (Kim et al., 1999; Lobner et al., 2000; Park et al., 2000) . As in brain ischemia, zinc neurotoxicity in cortical culture involves disturbances in energy metabolism. Sheline et al. (2000) showed that exposure to zinc causes inhibition of glyceraldehyde-3-phosphate dehydrogenase and depletion of ATP and NAD ϩ . Surprisingly, pyruvate, the end metabolite of glycolysis, normalizes depletion of ATP and NAD ϩ and protects almost completely against zinc toxicity .
If the neuroprotective effect of pyruvate is as remarkable in animal models of brain ischemia as in zinc neurotoxicity in cortical culture, pyruvate may be an ideal neuroprotectant in human ischemic stroke. To examine this, we tested the protective effect of pyruvate in a rat model of transient forebrain ischemia. Here we report that intraperitoneal pyruvate given within 1 hr after the reperfusion almost completely blocks neuronal injury in this model.
MATERIALS AND METHODS
Cortical cell culture and e xposure to toxins. Mixed cortical cell cultures, containing both neurons and astrocytes, were prepared as described previously (Koh et al., 1996; K im et al., 1999) from fetal mice at 14 -15 d of gestation. Briefly, dissociated cortical cells were plated onto a previously established astroglial cell monolayer at three hemispheres per 24-well plate (Nunc, Rochester, N Y) in a plating medium [DM EM (Life Technologies, Rockville, MD) supplemented with 20 mM glucose, 38 mM sodium bicarbonate, 2 mM glutamine, 5% fetal bovine serum, and 5% horse serum]. C ytosine arabinoside (10 M) was added 5-6 d after plating to halt the growth of non-neuronal cells. Glial cultures were prepared from neocortices of newborn mice (postnatal day 1-3) and plated at 0.5 hemispheres per 24-well plate, in the same plating medium but supplemented with 10% fetal bovine serum and 10% horse serum. Astroglial cultures were used for plating between 14 and 28 d in vitro, when they form a confluent monolayer. Continuous exposure to toxins (zinc as ZnCl 2 , NMDA, glutamate, and ionomycin) without or with an addition of 5 mM pyruvate (Sigma, St. L ouis, MO) was done in M EM. After 24 hr of the exposure onset, neuronal death was estimated.
Transient cerebral ischemia of the rat. All animal experiments were performed in accordance with the Guide of Ulsan University for C are and Use of Laboratory Animals. Male adult Sprague Dawley rats weighing 290 -310 gm were used for experiments. Under halothane anesthesia, both common carotid arteries were ligated for 12 min. At the same time, systemic mean arterial pressure was lowered to 50 Ϯ 5 mmHg by withdrawing blood from femoral artery into heparinized syringe. Core body temperature was maintained at 37 Ϯ 1.0°C using a heating blanket (Harvard, South Natick, M A) and lamp during and for 2 hr after the ischemia. Perf usion was restored by unligating the arteries and reintroducing the blood.
Sodium pyruvate (500 mg / kg) dissolved in water was given to rats by intraperitoneal injection at various times as indicated. As controls, osmolarity-matched NaC l (104.5 mg / kg) solution was injected intraperitoneally. In some experiments, different doses of sodium pyruvate (250 or 1000 mg / kg) were given. For tissue examination, brains were harvested at 72 hr after the ischemia, except in cases in which brains were obtained at 15 or 30 d.
T issue preparation and zinc-specific fluorescence staining. Coronal brain sections (10-m-thick) (anteroposterior, 4.0 mm from the bregma) were prepared using a cryostat and mounted on prechilled glass slides coated with poly-L-lysine. Unfixed brain sections were stained for 90 sec with the zinc-specific fluorescent dye N-(6-methoxy-8-quinolyl)-p-carboxybenzoylsulphonamide (TFL-Zn) (Calbiochem, La Jolla, CA) (Budde et al., 1997; Lee et al., 2000) dissolved in Tris buffer (0.1 mM, pH 8.0). After washing with saline, TFL-Zn-stained sections were examined under a fluorescence microscope (excitation, 355-375 nm; dichroic, 380 nm; barrier, 420 nm) (BX60; Olympus Optical, Tokyo, Japan) and photographed with a digital camera (Camedia C2000; Olympus Optical).
Assessment of neuronal death. Morphological changes of neuronal cell death in cortical culture were observed under a phase-contrast microscope (I X70; Olympus Optical). To identif y dead neurons, cultures were stained with 0.4% trypan blue for 3 min. Numbers of trypan blue-stained cells were counted in five randomly chosen fields (200ϫ). Percentage of neuronal cell death was calculated by dividing the number of trypan blue-positive neurons by the mean number of neurons in control cultures.
To quantif y neuronal cell death in the brain sections, brain sections were processed for terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling (TUN EL) staining with the in situ cell death detection kit (Boehringer Mannheim, Mannheim, Germany). Briefly, after fixation in 4% paraformaldehyde and incubation in permeabilization solution (0.1% Triton X-100 in 0.1% sodium citrate), sections were incubated with TUN EL reaction mixture at 37°C. The TUN ELstained sections were examined under a fluorescent microscope and photographed. Subsequently, the same sections were stained with 0.5% cresyl violet to evaluate surviving neurons.
TUN EL -positive neurons and surviving neurons with intact morphology on cresyl violet-stained slides were counted bilaterally in the marked areas (see Fig. 3F ) of CA1, CA3, and dentate gyrus with Image-Pro Plus computer-assisted image analysis program (Media C ybernetics, Silver Spring, MD). Statistical analysis were performed by a two-tailed paired t test, and p Ͻ 0.05 was considered statistically significant.
RESULTS
Before doing experiments in the rat, we determined the spectrum of pyruvate neuroprotection in cortical culture. As reported previously , neuronal death induced by 24 hr exposure to 35 M zinc was completely blocked by 5 mM pyruvate in cortical culture ( Fig. 1 A,B) . However, calcium-overload neuronal death induced by 24 hr exposure to NMDA (Fig. 1C,D) , glutamate, or ionomycin was not attenuated by pyruvate (Fig.  1 E) . This result indicates that pyruvate is a potent protectant against zinc toxicity but not against calcium-overload toxicity.
Next we examined the effect of pyruvate on transient forebrain ischemia. Transient (12 min) forebrain ischemia was delivered as described in Materials and Methods. Compared with shamoperated rats, rats subjected to ischemia exhibited decreased activity after the surgery. In some, salivation, tremor, startle responses, or wet-dog shakes started to show in 30 min to 1 hr after ischemia. NaCl (104.5 mg/kg, equimolar to 500 mg/kg sodium pyruvate) or sodium pyruvate (500 mg/kg) solution was intraperitoneally injected 30 min after the onset of reperfusion. The NaCl injection did not alter the behavior of ischemiasubjected rats. In contrast, the pyruvate treatment abolished salivation, tremor, startling, and wet-dog shakes after ischemia, if had been present.
The next conspicuous effect of pyruvate treatment was a re- markable decrease in mortality associated with transient forebrain ischemia. Compared with the high mortality (58.1%) of NaCl-injected rats, the mortality of rats injected with sodium pyruvate (500 mg/kg) at 0 -1 hr after reperfusion was 3.8% (only 1 of 26 rats died) ( Table 1) . In some rats, sodium pyruvate was injected either 30 min before or 2 and 3 hr after the onset of reperfusion; in these groups, mortality was 44.4, 100, and 42.9%, respectively (Table 1) . At 72 hr after the 12 min ischemia, severe neuronal death in hippocampus and cortex was seen in brains of survived NaClinjected control rats. TUNEL staining showed widespread nuclear DNA breakage in hippocampal and cortical neurons (Fig.  2 A, C) . The widespread neuronal death was confirmed by cresyl violet staining; degenerating neurons exhibited severe pyknosis (Fig. 2 A, C, insets) . All of the dead neurons in hippocampus and cortex exhibited dense zinc accumulation in perikarya (Fig.  2 E, G) . Similarly extensive neuronal death was evident in rats injected with sodium pyruvate (500 mg/kg) 30 min before reperfusion or 3 hr after ischemia. However, in rats injected with sodium pyruvate (500 mg/kg) at 0 min, 30 min, or 1 hr after the onset of reperfusion, virtually no neuronal cell death was found in cortex or hippocampus (Fig. 2 B, D) . In these groups, no zinc accumulation in neuronal cell bodies was seen (Fig. 2 F, H ).
Surviving neurons with intact nuclei and no pyknosis were counted in the marked areas (Fig. 3F ) of CA1, CA3, and dentate gyrus in cresyl violet-stained hippocampal sections (Fig. 3A) . To additionally quantify dead neurons, TUNEL-stained neurons were counted in the same areas (Fig. 3B) . Twelve minutes of ischemia produced rather severe injury involving all of the areas of hippocampus in the NaCl-treated control rats. However, the same ischemia produced almost no neuronal death in rats intraperitoneally injected with 500 and 1000 mg/kg pyruvate 30 min after the onset of reperfusion (Fig. 3 A, B) . On the other hand, the 250 mg/kg dose of pyruvate was modestly protective only in CA3 but not in CA1 or dentate gyrus. At 500 and 1000 mg/kg doses of pyruvate, cortical neurons were also almost completely protected (data not shown).
Next, the dose of pyruvate was fixed at 500 mg/kg, and the injection time was varied. When administered 0 -1 hr after the onset of reperfusion, almost complete protection was seen in all three areas of hippocampus (Fig. 3C,D) . However, when pyruvate was given 30 min before the reperfusion, only modest protection was seen in CA3 and dentate gyrus but not in CA1. Pyruvate given 3 hr after the onset of reperfusion had no protective effect at all (Fig. 3C,D) .
Finally, we examined whether the protective effect of pyruvate was transitory or long lasting. At 15 and 30 d after 12 min ischemia, brains of rats given NaCl or sodium pyruvate (500 mg/kg) injection at 30 min after the onset of reperfusion and were harvested, and the numbers of surviving neurons were counted in the above marked areas (Fig. 3F ) in hippocampus. Because the dead neurons may have disappeared at these time points, surviving neurons in cresyl violet-stained sections were counted. Cell counting revealed that the near-complete neuroprotective effect of pyruvate remained virtually unchanged over the 30 d time period after the ischemia (Fig. 3E) . These data suggest that protective effect of pyruvate is long lasting and likely permanent.
DISCUSSION
The core finding of the present study is that administration of pyruvate, when given within 1 hr after the onset of reperfusion, is remarkably neuroprotective in rats against transient cerebral ischemia, which produced neuronal death throughout hippocampus. Whereas the overall mortality associated with 12 min forebrain ischemia was 58.1%, pyruvate injection between 0 and 1 hr after the onset of reperfusion drastically decreased it to 3.8%. In addition, the histological protection was so spectacular that no sign of brain damage was found in most of rats. Furthermore, all Table 1 . Mortality of rats subjected to 12 min forebrain ischemia NaCl, 30 min after the onset of reperfusion 18 of 31 (58.1%) Pyruvate, 30 min before the onset of ischemia 4 of 9 (44.4%) Pyruvate, at the time of reperfusion 0 of 5 (0%) Pyruvate, 30 min after the onset of reperfusion 1 of 16 (6.3%) Pyruvate, 1 hr after the onset of reperfusion 0 of 5 (0%) Pyruvate, 2 hr after the onset of reperfusion 4 of 4 (100%) Pyruvate, 3 hr after the onset of reperfusion 3 of 7 (42.9%)
Total of 77 adult rats were used for experiments. NaCl (104.5 mg/kg) or sodium pyruvate (500 mg/kg) was intraperitoneally injected at the indicated time in relation to the onset of ischemia or reperfusion. Figure 2 . Protection of hippocampal and cortical neurons by pyruvate against transient cerebral ischemia. Hippocampal CA1 (A, B) and parietal cortex (C, D) of rats that underwent 12 min forebrain ischemia followed 30 min later by intraperitoneal injection of NaCl (A, C) solution or sodium pyruvate (500 mg/kg; B, D) solution were stained with TUNEL or cresyl violet (insets). Whereas almost complete neuronal damage is evident in A and C, no damage is seen in B and D. Hippocampal CA1 (E, F ) and parietal cortex (G, H ) of rats that underwent 12 min forebrain ischemia followed 30 min later by intraperitoneal injection with NaCl (E, G) or sodium pyruvate (500 mg/kg; F, H ) were stained with TFL-Zn 72 hr after ischemia. Chelatable zinc is visualized as green-blue fluorescence. Dense zinc accumulation in degenerating or dead neuronal cell bodies is seen in NaCl-treated control brains (E, G) . No zinc accumulation in neuronal cell bodies is seen in pyruvate-treated cases (F, H ). Scale bar, 50 m. Figure 3 . Quantification of pyruvate neuroprotection in hippocampus. A, Surviving neurons were estimated by cresyl violet staining. Bars denote the number (mean Ϯ SEM; n ϭ 5 each) of intact neurons in each area in sham-operated rats or rats subjected to 12 min ischemia followed by intraperitoneal injections of NaCl or indicated doses of sodium pyruvate 30 min later. B, Dead neurons were estimated by the TUNEL staining in the same sections as in A. Bars denote the number TUNEL-positive neurons. Virtually no TUNEL-positive neurons were seen in sham-operated rats or rats given 500 or 1000 mg/kg sodium pyruvate. C, Bars denote the number of intact neurons in rats (n ϭ 5 each) subjected to 12 min ischemia followed by intraperitoneal sodium pyruvate injections (500 mg/kg) at 30 min before or 0 min, 30 min, 1 hr, or 3 hr after the onset of reperfusion. Whereas pyruvate injections at 0 -1 hr after ischemia almost completely protected hippocampal neurons, pyruvate injections at 30 min before or 3 hr after the reperfusion protected only minimally. D, TUNEL-positive neurons were counted in the same areas of the above rats. E, Black bars denote surviving neurons in the marked areas in cresyl violet-stained hippocampi of NaCl-injected rats obtained 15 and 30 d after 12 min ischemia (n ϭ 5 each). Gray bars denote surviving neurons in hippocampi of pyruvate-injected rats (30 min after the reperfusion; 500 mg/kg) obtained 3, 15, and 30 d after ischemia. F, A cresyl violet-stained hippocampal section of a normal rat. Boxes (820 ϫ 615 m) denote the areas for cell counting. All counting was performed bilaterally. A, B, #p Ͻ 0.001 denotes difference from the sham-operated groups; two-tailed t test with Bonferroni correction for multiple comparisons. A-E, *p Ͻ 0.05 represents differences from corresponding NaCl-injected groups.
of the pyruvate-rescued neurons seemed to be surviving even 30 d after ischemia. Naturally, the time window of opportunity for pyruvate protection was not permanent and disappeared when given at 2 or 3 hr after the reperfusion. The protective time window of pyruvate treatment, 0 -1 hr after the onset of reperfusion, is clinically exploitable in the context of cardiac arrest. Whereas resuscitative efforts often restore perfusion to the brain, still a number of patients end up having permanent brain damage, because only minutes of global ischemia can trigger processes leading to permanent brain damage (Pulsinelli et al., 1982; Smith et al., 1984) . Hence, if pyruvate proves as remarkably protective in humans as in rats, resuscitation followed by pyruvate treatment within 1 hr would save a number of patients from permanent brain damage. It is not clear why pyruvate given 30 min before reperfusion showed only modest protective effect. This may be attributable to rapid degradation of pyruvate or to the conversion of pyruvate to potentially harmful lactate during ischemia (Petito et al., 1987) . In contrast, pyruvate given after reperfusion may be preferentially used in the Krebs' cycle.
Protective doses of pyruvate given intraperitoneally in the present study are 250 -1000 mg/kg. Although pharmacokinetic data are not available in this case because pyruvate is rapidly and efficiently transported across the blood-brain barrier (Pardridge and Oldendorf, 1977; Miller and Oldendorf, 1986) , these systemic doses may be sufficient to deliver protective concentrations of pyruvate to the brain. Future studies may provide information regarding pharmacokinetics of intraperitoneally injected pyruvate.
Although glutamate antagonists may be effective against ischemic neurodegeneration (Simon et al., 1984; Foster et al., 1988; Judge et al., 1991; Diemer et al., 1992) , a significant limitation is that their neuroprotective effect is not long lasting (Colbourne et al., 1999) . In contrast, the neuroprotective effect of pyruvate persisted even at 30 d after the insult, without noticeable side effects.
Whereas the extent and the sustainability of pyruvate neuroprotection in vivo seen in the present study are quite remarkable and surprising, pyruvate neuroprotection per se is not new. Introduction of pyruvate in glucose-deprived neurons restored excitatory postsynaptic potentials and blocked a neuronal damage in hippocampal slice or cultured neurons (Izumi et al., 1994; Matsumoto et al., 1994; Izumi et al., 1997) . Moreover, pyruvate has been shown to protect neurons against various insults (Desagher et al., 1997; Ruiz et al., 1998; Maus et al., 1999) .
Although elucidation of the mechanism of pyruvate neuroprotection is beyond the scope of the present study, it is likely that normalization of disturbances in energy metabolism may be involved. As Sheline et al. (2000) showed, 4 mM pyruvate normalized ATP and NAD ϩ levels in zinc-exposed neurons and protected them against zinc toxicity. Interestingly, our culture data indicate that the protective effect by 5 mM pyruvate was almost complete in zinc toxicity but not seen in the continuous exposure paradigms of calcium-overload neurotoxicity. However, in a study using a pulse exposure paradigm in the absence of glucose, 5 mM pyruvate reduced NMDA-induced neuronal death, albeit modestly in striatal cultures (Maus et al., 1999) . Without knowing which paradigm is more appropriate in vivo, it appears possible that calcium excitotoxicity may be one of the targets of pyruvate protection. However, the fact that 5 mM pyruvate almost completely protected against zinc neurotoxicity in our cortical culture seems to strongly favor zinc neurotoxicity as the main target of pyruvate protection in the case of transient cerebral ischemia.
Regardless of the precise protective mechanism of pyruvate against ischemic brain injury, the important fact is that pyruvate is a cheap, easily administrable, innocuous, and most importantly, remarkably neuroprotective substance. Expedient clinical trials seem to be warranted.
